3996-29-0Relevant articles and documents
MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
-
Paragraph 0620, (2021/01/23)
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
Design, synthesis and biological evaluation of oxime lacking Psammaplin inspired chemical libraries as anti-cancer agents
Ali, Kasim,Chaturvedi, Priyank,Datta, Dipak,Kumar M, Srinivas Lavanya,Meena, Sanjeev,Panda, Gautam
, (2020/10/02)
In this study, we attempted the chemical simplification of Psammaplin (PsA), while retaining its activity in vitro. Inspired by the previous Structure Activity Relationship (SAR) studies on various PsA analogues and relying on the fact that oxime is metabolically unstable, we initially designed and synthesized a diverse library of PsA analogues and evaluated for cytotoxic activity. Among 32 compounds of Psammaplin analogues synthesized, the compound 10b was almost equally active as parent Psammaplin in vitro.
RETRACTED ARTICLE: Design, synthesis, and biological evaluation of heterotetracyclic quinolinone derivatives as anticancer agents targeting topoisomerases
Lee, Jiann-Fong,Chang, Ting-Yu,Liu, Zheng-Fang,Lee, Nian-Zhe,Yeh, Yen-Hsiu,Chen, Yi-Song,Chen, Tsung-Chih,Chou, Hao-Syun,Li, Tsai-Kun,Lee, Sung-Bau,Lin, Mei-Hsiang
, (2020/02/11)
A series of thiochromeno[2,3-c]quinolin-12-one derivatives with various substitutions were synthesized and evaluated as topoisomerase (Topo) inhibitors. Six (8, 10, 12, 14, 19, and 26) of 23 compounds showed strong inhibitory activities against Topo-media
